Telix Pharmaceuticals

Telix Pharmaceuticals Receivables

The Accounts Receivable of Telix Pharmaceuticals (TLX.AX) as of Nov 22, 2026 is 129.20 M USD. In the previous year, Accounts Receivable was 86.93 M USD — a change of 48.63% (higher).

Receivables

129.20 MUSD

YoY

48.63%

Last updated:

Accounts Receivable of Telix Pharmaceuticals is 2025 129.20 M USD. Accounts Receivable of Telix Pharmaceuticals was 2024 86.93 M USD. It decreases by 48.63% higher compared to the previous year.

The Telix Pharmaceuticals Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2019
745,000.00 USD
Jan 1, 2020
160,000.00 USD
Jan 1, 2021
730,000.00 USD
Jan 1, 2022
25.52 M USD
Jan 1, 2023
44.04 M USD
Jan 1, 2024
86.93 M USD
Jan 1, 2025
129.20 M USD
The Telix Pharmaceuticals Receivables history
YEARReceivablesYoY
129.20 MUSD+48.63%
86.93 MUSD+97.38%
44.04 MUSD+72.57%
25.52 MUSD+3,396.04%
730,000.00USD+356.25%
160,000.00USD-78.52%
745,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telix Pharmaceuticals stock

Accounts Receivable of Telix Pharmaceuticals is 129.20 M USD in 2025.

Accounts Receivable of Telix Pharmaceuticals changed from 86.93 M USD to 129.20 M USD, representing a 48.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Telix Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals